STOCK TITAN
  1. Home
  2. Sec-filings
  3. NVAX
  4. [Form 4/A] NOVAVAX INC Amended Insider Trading Activity

Novavax (NVAX) EVP granted 177,500 options with revised terms

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4/A

Rhea-AI Filing Summary

Novavax executive Elaine O’Hara, EVP and Chief Strategy Officer, filed an amended Form 4 to correct the exercise price previously reported for a 2026 non-statutory stock option grant covering 177,500 shares awarded on March 2, 2026. All other details from the earlier filing remain unchanged.

Under this option, one-quarter of the shares vest on the first anniversary of March 2, 2026, and the remaining three-quarters vest in equal monthly installments over the following three years, subject to her continued employment with the company.

Positive

  • None.

Negative

  • None.
Insider O'Hara Elaine
Role EVP, Chief Strategy Officer
Type Security Shares Price Value
Grant/Award 2026 Non-statutory Stock Option NQ 177,500 $0.00 --
Holdings After Transaction: 2026 Non-statutory Stock Option NQ — 177,500 shares (Direct)
Footnotes (1)
  1. This Form 4/A has been filed solely to amend the exercise price as originally reported in Column 2 and price of derivative security as originally reported in Column 8 of Table II of the Reporting Person's Form 4 filed on March 3, 2026. All other information remains unchanged from the March 3, 2026 filing. One-quarter (1/4) of the shares subject to this option granted under the Plan vest on the first anniversary of March 2, 2026, and the remaining three-quarters (3/4) of the shares vest in equal monthly installments over the following three (3) years, in each case subject to continued employment with the Company through such vesting date.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
O'Hara Elaine
(Last) (First) (Middle)
21 FIRSTFIELD ROAD
(Street)
GAITHERSBURG MD 20878
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
NOVAVAX INC [ NVAX ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
EVP, Chief Strategy Officer
3. Date of Earliest Transaction (Month/Day/Year)
03/02/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
03/03/2026 		6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
2026 Non-statutory Stock Option NQ $10.11(1) 03/02/2026 A 177,500 (2) 03/02/2036 Common Stock 177,500 $0(1) 177,500 D
Explanation of Responses:
1. This Form 4/A has been filed solely to amend the exercise price as originally reported in Column 2 and price of derivative security as originally reported in Column 8 of Table II of the Reporting Person's Form 4 filed on March 3, 2026. All other information remains unchanged from the March 3, 2026 filing.
2. One-quarter (1/4) of the shares subject to this option granted under the Plan vest on the first anniversary of March 2, 2026, and the remaining three-quarters (3/4) of the shares vest in equal monthly installments over the following three (3) years, in each case subject to continued employment with the Company through such vesting date.
/s/ Mark J. Casey, Attorney-in-Fact 03/09/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What did Novavax (NVAX) disclose in Elaine O’Hara’s latest Form 4/A?

Novavax reported that EVP and Chief Strategy Officer Elaine O’Hara amended a prior Form 4 to correct the exercise price for a 177,500-share non-statutory stock option granted on March 2, 2026, while leaving all other reported information unchanged.

How many Novavax stock options were involved in Elaine O’Hara’s Form 4/A?

The amended filing involves a non-statutory stock option covering 177,500 shares of Novavax common stock. This option was originally granted on March 2, 2026, and the amendment solely updates the reported exercise price, not the number of options or other terms.

Did Elaine O’Hara buy or sell Novavax (NVAX) shares in this Form 4/A?

No open-market buy or sell occurred. The Form 4/A reflects an option grant acquisition, amending the exercise price of a 2026 non-statutory stock option for 177,500 shares, rather than a purchase or sale of Novavax common stock in the market.

What is the vesting schedule of Elaine O’Hara’s 2026 Novavax stock option grant?

The filing states that one-quarter of the option shares vest on the first anniversary of March 2, 2026. The remaining three-quarters vest in equal monthly installments over the next three years, conditioned on her continued employment with Novavax through each vesting date.

What changed compared with Elaine O’Hara’s prior Novavax Form 4 filed March 3, 2026?

The amended Form 4/A was filed solely to correct the exercise price reported for the 2026 non-statutory stock option in the original March 3, 2026 filing. The company states that all other information from that prior Form 4 remains the same.